Internal Medicine, Cardiovascular Disease · Torrance, CA
NPI
1316957228
Since 2006
Specialty
Internal Medicine, Cardiovascular Disease
Code 207RC0000X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
21840 Normandie Ave, Ste. 700
Torrance, CA, 90502
Phone (310) 222-5101
Groups this clinician bills Medicare through
Medicare paid, 2024
$9,082
123 services
Medicare patients, 2024
26
Average age 69
Drug cost, 2024
$6.1M
699 prescriptions
Company payments, 2025
$121K
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ronald J Oudiz was code 99214 (office e&m - established), 50 times for 19 patients. In total Ronald J Oudiz billed 123 services in 10 codes, and Medicare paid $9,082.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-08-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 50 | 19 | $108.19 | $5,409 |
| 94618 Pulmonary Function Testing | Office | 32 | 18 | $28.72 | $919 |
By year: 2022 $8,647 for 101 services; 2023 $5,782 for 80 services; 2024 $9,082 for 123 services.
Medicare prescription drug claims, 2024
In 2024, the drug Ronald J Oudiz prescribed most often to Medicare patients was Ambrisentan, with 136 prescriptions and refills. In total Ronald J Oudiz wrote 699 Medicare prescriptions that cost $6.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ambrisentan Generic | 136 | 166 | 20 | $698K |
| Uptravi Selexipag | 113 | 113 | 12 | $2.4M |
| Tadalafil Generic | 108 | 132 | 17 | $93K |
| Winrevair Sotatercept-Csrk | 49 | 49 | Under 11 | $681K |
| Opsumit Macitentan | 49 | 51 | Under 11 | $608K |
| Sildenafil Citrate Generic | 48 | 85 | Under 11 | $18K |
| Orenitram Er Treprostinil Diolamine | 25 | 25 | Under 11 | $626K |
| Tyvaso Dpi Treprostinil | 21 | 21 | Under 11 | $515K |
| Furosemide Generic | 15 | 33 | Under 11 | $114 |
| Opsynvi Macitentan/Tadalafil | 15 | 21 | Under 11 | $271K |
| Letairis Ambrisentan | 13 | 15 | Under 11 | $148K |
| Omeprazole Generic | 13 | 13 | Under 11 | $170 |
| Bosentan Generic | 12 | 12 | Under 11 | $27K |
| Potassium Chloride Generic | 11 | 32 | Under 11 | $455 |
| Digoxin Generic | 11 | 33 | Under 11 | $375 |
Brand drugs: 298 claims; generic drugs: 401 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ronald J Oudiz $121K ($121K in general payments such as food, travel and fees) from 11 companies. The largest payer was Merck Sharp & Dohme LLC with $70K.
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC MRK | 51 | $70K |
| Actelion Pharmaceuticals US, Inc. JNJ | 40 | $32K |
| United Therapeutics Corporation UTHR | 18 | $18K |
| AOP Health US, LLC | 2 | $839 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 6 | $170 |
| Liquidia Technologies, Inc. | 2 | $61.41 |
| BridgeBio Pharma, Inc. BBIO | 2 | $41.28 |
| Regeneron Healthcare Solutions, Inc. REGN | 1 | $35.55 |
| Invivyd Inc IVVD | 1 | $31.36 |
| Scpharmaceuticals Inc. SCPH | 1 | $25.42 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.